G. Moureau

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

This study compares the SARS-CoV-2 Alpha variant and G614 strain in Syrian hamsters, finding similar replication and disease outcomes but a slight fitness advantage for G614.

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.

This study re-encodes the Yellow Fever Virus genome with synonymous mutations to create attenuated strains, finding that certain mutations reduce virulence without significantly affecting replication fitness.